New York, New York (PRWEB) May 10, 2012
Bernstein Liebhard LLP reports on a new U.S. Food and Drug Administration (“FDA”) analysis published on May 9, 2012 that cautions against long term use of Fosamax due to its uncertain benefits and the possibility of bisphosphonate complications.* The FDA review, published in The New England Journal of Medicine, came after growing debate on the side effects of long term use of Fosamax and other bisphosphonates. The Agency’s systematic review analyzed only long term use of bisphosphonates and found that the drugs offered little, if any, benefit after three to five years of use. As reported by the New York Times, experts are concerned that in certain cases of long term use, the drugs may lead to weaker bones in post-menopausal women and cause other bisphosphonate complications such as femur fractures, esophageal cancer and osteonecrosis of the jaw.** Although the FDA did not issue specific guidelines for the duration of use, the analysis did suggest heightened awareness of the risks of long term use of Fosamax and other bisphosphonates.
Long Term Use of Fosamax And Other Bisphosphonates Unnecessary For Many
According to the New York Times, some women with moderate bone density and no other risk factors are unlikely to derive benefits from long term use of bisphosphonates, yet continued to take these medications for years. Dr. Clifford J. Rosen, an endocrinologist and researcher at the Maine Medical Center Research Institute told the New York Times, “I think a lot of people are going to come off this drug.” In an accompanying article in The New England Journal of Medicine by Dr. Rosen and others, the researchers estimated that 60 to 70 percent of current users should consider discontinuing using the drugs after three to five years. According to the study, women who have been diagnosed with osteopenia, a mild version of low bone density, are especially good candidates to stop taking bisphosphonates after three to five years, particularly in light of the recent safety concerns.
Bisphosphonate Complications Lead To Mounting Litigation
Individuals who have experienced bisphosphonate complications such as atypical femur fractures are filing lawsuits against the drug manufacturers. The lawyers at Bernstein Liebhard LLP are currently representing clients who suffered from bisphosphonate complications after long term Fosamax use. The Firm is actively filing cases on behalf of these individuals in the Superior Court of New Jersey, Atlantic County, in In re: Fosamax Litigation (No. 282 N.J. Super. Ct.). Those who took Fosamax and sustained a femur fracture may be entitled to compensation for medical bills, pain and suffering, lost wages and other injuries.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past nine consecutive years. Only two firms in the country have been selected for the Hot List nine years in a row.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2012 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP